INTRODUCTION
Co-administration of antiretroviral therapy regimen with non-antiretroviral drugs (non-ARVs) is inevitable because the usage of the former by people living with HIV/AIDS (PLWHA) is lifelong and this put them among the therapeutic drugs for the risk of clinically significant interactions with other concomitantly administered 1 drugs. There are six main classes of ARV drugs currently available for treatment of HIV/AIDS infection. They include the Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs/NtRTIs) such as zidovudine (AZT), lamivudine (3TC), stavudine (d4T), abacavir (ABC), emtricitabine (FTC) and tenofovir 2 (TDF); the Non-Nucleoside reverse transcriptase inhibitors (NNRTI) such as the first generation NNRTIs (nevirapine, delavirdine and efavirenz) and the second 3 generation NNRTIs (etravirine and rilpivirine); the Protease Inhibitors (PIs) e.g. amprenavir ( APV), fosamprenavir (FPV), atazanavir (AZV), indinavir (IDV), nelfinavir (NFV), lopinavir (LPV), ritonavir (RTV), 4 saquinavir (SQV), darunavir and tipranavir; the entry or 5 CCR5 inhibitor such as maraviroc; the fusion inhibitor 6 e.g. Enfuvirtide; and finally the Integrase inhibitors (also known as integrase nuclear strand transfer inhibitors or INSTIs) e.g. raltegravir, elvitegravir and 7 dolutegravir. Other classes are at various stages of development but are not yet widely available for clinical use. The types of combinations of antiretroviral drugs (ARVs) used by PLWHA may differ slightly from country to country depending on the recommendations in the national guidelines of each country which is also predicated on the World Health Organization (WHO) 8 guidelines for the use of ARVs. It is recommended that three or more ARV drugs from at least two different classes, known as highly active antiretroviral therapy (HAART) be used to reduce the risks for development of 9 resistance by HIV. The first line regimen usually include two nucleoside reverse transcriptase inhibitors (NNRTIs) and a non-nucleoside reverse transcriptase inhibitors (NNRTIs) or a protease inhibitors (PI) and selections are made based on availability, accessibility, 9 affordability, efficacy and ease of administration. The 2010 national guideline in Nigeria recommends the phasing out of Stavudine (d4t), based on WHO's recommendation in 2009, due to its adverse effects (lipoatrophy, peripheral neuropathy and lactic acidosis) 10 which persisted even after dose reduction In Nigeria, the following are the preferred first line regimens for ART naïve adults : zidovudine + lamivudine + efavirenz (AZT + 3TC + EFV), zidovudine + lamivudine + nevirapine (AZT + 3TC + NVP ), tenofovir + lamivudine or emtricitabine + efavirenz (TDF +3TC (or FTC) + EFV) and tenofovir + lamivudine or emtricitabine + nevirapine 10 (TDF +3TC (or FTC) + NVP). In addition, triple NRTIs such as AZT + 3TC + ABC or AZT + 3TC + TDF could be used as an alternative first line regimen in special situations such as intolerance or contraindications to both NNRTI regimens, particularly in HIV/TB co-infection; pregnant women; chronic viral 10 hepatitis B and in HIV-2 infection. When treatment fails with the first line regimen, the patient is switched to the second line ART which usually include a boosted protease inhibitor (bPI) such as atazanavir/ritonavir (ATV/r) or lopinavir/ritonavir (LPV/r) plus two nucleoside analogues (NRTIs); one of which must be different from the type used as first line 10 regimen. A regimen of AZT+3TC+TDF+LPV/r (or ATV/r) is recommended for PLWHA co-infected with hepatitis B. If therapeutic failure is experienced with the second line ART regimen and other available regimens, a 'Salvage Therapy' is offered after ruling out adherence and drug interaction issues and after conducting genotype or phenotype resistance tests. The salvage therapy regimen, which usually contains at least two active agents, include ritonavir boosted darunavir (DRV/r) plus raltegravir (RAL) with an optimized 10 background of NRTIs which should include 3TC/FTC. The non-ARV drugs commonly co-prescribed with ARV drugs in PLWHA are those that are used for the treatment of comorbid ailments or for the prophylaxis and treatment of opportunistic infections. They include antibiotics, anti-tuberculous, antifungals, analgesics 11, 12, 13 and antimalarial drugs.
However, the types used may vary from country to country depending on the endemic nature of the co-existing diseases . For example, Chagas disease, which occurs in severely immunocompromised patient, is endemic in Latin 14 America and is treated with Benzimidazole or 15 nifurtimox. Malaria, on the other hand, is endemic in 12 Nigeria, sub-Saharan Africa and Southeast Asia. Hence prescriptions of antimalarial drugs for both treatment and prophylaxis are expected to be more in such regions. HIV-infected people with a low CD4 cell count 16 were found to be at increased risk of severe malaria. Atovaquone-proguanil, chloroquine phosphate, mefloquine, sulphadoxine/pyrimethamine or combination with quinine), clindamycin (used in combination with quinine), artesunate (not licensed for use in the United States, but available through the CDC 18 malaria hotline) are used for treatment with 19 chloroquine being safe in pregnancy. Other numerous non-ARV drugs, depending on the co-existing opportunistic or concomitant infections, have been co- [20] [21] [22] [23] [24] [25] [26] [27] prescribed with ART regimen for PLWHA Only few studies have documented the types of drugs used in HIV/AIDS in Nigeria. This study aimed to identify drugs for opportunistic infections or other co-morbid conditions that are frequently prescribed for PLWHA attending LUTH HIV clinic and to assess the frequency of prescriptions of the first, second and third lines ART regimen.
METHODS

Study design
This is a five-year cohort study in which the prescriptions for the eligible patients, between January 2009 and June 2014, at the AIDS Prevention Initiative in Nigeria (APIN) clinic, Lagos University Teaching Hospital (LUTH) in Nigeria were reviewed.
Study center
The APIN clinic is one of the United States Presidential Emergency Plan for AIDS Relief (PEPFAR)-funded centers for HIV relief program. The clinic is run between 8 am and 4 pm on every Monday to Friday, excluding public holidays. It consists of eight units including the medical unit which has a total of 18 doctors; comprising four consultants, eight residents, and an average of six medical officers. It also has a pharmacy unit which has at least four pharmacists attending to patients simultaneously. Others are nursing, hematology, counseling, record, administrative and data units. An average of 350 old and new patients (adults and children) are attended to daily at the APIN clinic. ARV drugs are dispensed to registered patients free of charge either every two months or monthly, depending on the stability of the patient and stock level of the drugs. However, non-adherent patients are supplied a few quantity of drugs after being counselled until their adherence becomes adequately improved. Patients are usually followed up at the outpatient clinic every 4 weeks after ART commencement. Patients on concomitant treatment for malaria, opportunistic infections, and comorbid conditions or manifesting adverse drug effects are initially followed up weekly, then biweekly, and, later, every 4 weeks.
Sample size
Raosoft® sample size calculator was used to determine 36 the sample size . A sample size of 388 was calculated from the 13000 population of registered patients on ARV drugs using 5% error margin at 95% confidence interval, assuming 50% of the patients have all the measured outcomes documented in their case files. However, a sample size of 500 patients was used for ease of data analysis.
Patient selection
A total of 500 patients were randomly selected from 1893 who registered and commenced ART on or before year 2009. It was envisaged that the patients would develop co-morbid ailments or opportunistic infections, as well as manifest delayed adverse effect of antiretroviral drugs between January 2009 and June 2014. Patients were included if confirmed to be HIV positive by laboratory test, registered at APIN clinic on or before January 2009, already commenced on ART, maintained regular visit to the clinic, has documented regular laboratory tests, regularly obtain drugs from the clinic's pharmacy and still currently in the programme. However, patients are excluded if ARV-naïve, had only one or few visits to the clinic after commencement of ART and no longer in the programme due to transfer or self-discontinuation.
Data abstraction
Selection of the case notes of the 500 patients were predicated on regular attendance and availability of sufficient data on ARV and co-prescribed non-ARV drugs. A proforma form, purposively designed for this study was used for data abstraction.
Documentation of concurrent ailments and the non-ARVs drugs co-prescribed
The prescriptions were reviewed with a view to documenting all the non-ARV drugs used alone or concurrently with ARV drugs and vice versa. The frequency (f) and percentage (%) of the prescriptions containing CPD only, ARV drugs only, and those containing both (CPD/ARVs) were determined in order to know the most and the least prescribed CPD and ARV drugs. All the ailments for which the non-ARV drugs were prescribed were also documented.
Statistical analyses
Data extracted from the medical records were coded and results presented as frequency and percentage of total prescriptions. Prescriptions containing ARV drugs with co-prescribed non-ARV drugs such as those used for co-morbid ailments or for opportunistic infections were analyzed.
RESULTS
Demographics of the patients
A total of 500 (26.4%) patients out of 1894 registered in 2009 were enrolled for the study. The case files of all the 500 patients who commenced ARVs in 2009 were reviewed. The patients were comprised of 158 (31.6%) males and 342 (68.4%) females with a median age of 22 years (Interquartile range: (16 -177) years (Table 1) . 
Prescription Evaluation
A total of 22,458 prescriptions were issued from January 2009 to June 2014 to 500 patients whose case notes were randomly selected from those of the 1894 patients who registered at APIN clinic in 2009. ARV drugs prescription only were 12,397 (55%), CPD prescription only were 759 (3.4%), ARVs/CPD prescriptions were 9302 (41.6%). The mean number of prescription per patient was 44.9 + 5 standard deviation. (Table 2) Co-prescribed drugs in HIV treatment regimen (Table 3) followed by tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) (1468/9302; 15.78%). The least (95/9302; 1.02%) prescribed among the first line regimen was stavudine/lamivudine/nevirapine (d4T/3TC/NVP). The most and least prescribed second line ART regimens were TDF/FTC(AZT)(LPV/r) (330; 3.55%) and ABC/3TC(SQV/r) (1; 0.01%) respectively. W h i l e t h e o n l y t h i r d l i n e A R T r e g i m e n (ETR/DRV/RAL/RTV) co-prescribed with non-ARVs had very few prescriptions (30; 0.32%). (Table 3) Usman Sikiru 
Prescribed ART regimen
Co-morbid ailments and co-prescribed non-ARV drugs (CPD)
A total of 47 different non-ARV drugs were coprescribed with ARVs for the treatment/prevention of opportunistic infections and co-morbid ailments mainly bacterial infection, tuberculosis, malaria and mycoses. 8 Table 4a : Co-morbid ailments and co-prescribed non-ARV drugs with major prescriptions *ARVs/CPD: prescriptions containing both ARVs and non-ARVs (CPD). # for prophylaxis not treatment Co-prescribed drugs in HIV treatment regimen
DISCUSSION
The pattern of ART regimen usage in this study appears to be similar to those previously reported in other parts of the country. AZT/3TC/NVP regimen was the most prescribed in this study as similarly reported in other studies carried out in adults and children in HIV clinics in 11, 13, 37 Southwestern Nigeria. . This may be due to the fact that most of the clinics in which the studies were carried out were under the same HIV-treatment programme sponsored by PEPFAR/APIN which involves supply of antiretroviral drugs from the same source. It may also be because the prescribing pattern from all the centres conforms to the recommendation of the national 10 guidelines. The discontinuation of stavudine in 2010 as recommended by the same guideline, due to its adverse effects, may be responsible for its least prescription as first line ART regimen in this study. This study found antibacterials as the most (7761, 83.43%) commonly prescribed class of non-ARV drugs with co-trimoxazole being the most (7546, 81.12%) antibacterial prescribed. It is also the most prescribed among all the 47 listed co-prescribed non-ARV drugs.
Cough
Cough syrup (unbranded) 2 0.02
Emzolyn with codeine 1 0.01 Total (ARVs/CPD) 9302 100
Usman Sikiru WHO has recommended co-trimoxazole to patients 3 with CD4 cells count below 200 cells/mm for treatment 38 or prophylaxis against opportunistic infections such as pneumocystosis and toxoplasmosis. This may explain the high frequency of its prescription in this study. Cotrimoxazole prophylaxis has been shown to reduce morbidity and mortality among HIV-infected patients 39 with beneficial effects on CD4-cell count and viral load. The haematinics were the second most (511, 5.49%) commonly co-prescribed non-ARV drugs. This is because they are regularly dispensed to HIV-infected patients with impaired immunity to boost their immune system, improve their appetite and prevent anaemia. Anafi et al., also found multivitamins as the second most commonly co-prescribed non-ARV drugs in line 13 with our finding . The low proportions of prescriptions for antifungals (112, 1.2%) and drugs for other ailments associated with severe immunosuppression and opportunistic infections such as antivirals (17, 0.18%) and antidiarrhoeals (17, 0.18%) is an indication that most of the patients had good therapeutic outcome with HAART. Before antiretroviral therapy was discovered, fungal and other opportunistic infections were a major 43 problem for PLWHA. Since then, the numbers of fungal infections and deaths due to fungal infections in 43, 44 PLWHA have decreased substantially. The decrease in opportunistic infections is because antiretroviral therapy (ART) primarily helps keep people with HIV from reaching the stage where their immune systems are most vulnerable to fungal infections and other infections.
While the low proportion of prescriptions for malaria (157, 1.69%) may reflect the prophylactic effects of 46 47 antiretroviral drugs and co-trimoxazole against malaria, the prescriptions for analgesics (176, 1.89%), antihelminthics (5, 0.05%), antidepressants (8, 0.09%) and cough syrup (5, 0.05%) which also have low proportion are indications of good outcome of the antiretroviral therapy in the patients because the ailments are opportunistic conditions which occur 48 when the patients' immune function is compromised. Given the wide range of non-ARV drugs co-prescribed with ARV drugs in this study, there is a tendency for them to interact and possibly cause adverse toxicities. Further study will be required to assess this problem.
Conclusion
Co-trimoxazole was the most common non-ARV drug prescribed to PLWHA attending HIV-treatment centre in LUTH while AZT+3TC+NVP was the most commonly co-prescribed antiretroviral drug regimen. The first line ART regimen were more commonly prescribed than the second and third line ART regimens. The wide range of non-ARV drugs co-prescribed with ART regimens in this study would suggest a need to evaluate their potential interactions in future studies
